A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited ...

In the last reported quarter, U.S. sales of Keytruda were negatively impacted by around $250 million due to the timing of ...

RHHBY posts solid first-half 2025 growth on strong drug demand, but pipeline setbacks and biosimilar hits remain headwinds.

During a live event, Bruna Pellini, MD, discussed the efficacy of cemiplimab in PD-L1-high non–small cell lung cancer.

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

Roche’s checkpoint inhibitor Tecentriq has been cleared for another new use in the US – in melanoma – but could struggle to displace rival drugs from Bristol-Myers Squibb and Merck & Co. The ...

Patients with rheumatoid arthritis who undergo immune checkpoint inhibition for metastatic non-small cell lung cancer demonstrate similar overall survival as those without RA, according to data ...

Roche’s Tecentriq was the third PD-1/PD-L1 inhibitor to reach the market but is the first to be approved for any form of breast cancer.

Investors will focus on lead drug Cabometyx’ performance when Exelixis (EXEL) reports second-quarter 2025 results on July 28. The Zacks Consensus Estimate for sales and earnings is pegged at $527 ...

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launc ...

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.